"Prognostic importance of selected molecular genetic immunohistochemical markers and DNA ploidy in endometrial cancer."@en . "RIV/00098892:_____/11:#0000165!RIV12-MZ0-00098892" . "224390" . "3" . . . "Prognostick\u00FD v\u00FDznam vybran\u00FDch molekul\u00E1rn\u011B-genetick\u00FDch imunohistochemick\u00FDch marker\u016F a DNA ploidity u karcinomu endometria. Anotace \u010Desky: C\u00EDl studie: Studium nov\u00FDch vybran\u00FDch molekul\u00E1rn\u011B genetick\u00FDch imunomarker\u016F ( p53, c-erbB-2, Ki 67, bcl-2), hormon\u00E1ln\u00EDch receptor\u016F (ER,PR) a zm\u011Bn v bun\u011B\u010Dn\u00E9 ploidit\u011B n\u00E1dorov\u00FDch bun\u011Bk endometri\u00E1ln\u00EDho karcinomu a jejich komparace s hlavn\u00EDmi prognostick\u00FDmi faktory . V\u00FDsledky: U 71 % biologicky nezral\u00FDch endometri\u00E1ln\u00EDch tumor\u016F ( G3) se \u0161patnou progn\u00F3zou jsme prok\u00E1zali p\u0159\u00EDtomnost aneuploidn\u00EDch karyotyp\u016F , zat\u00EDmco u n\u00E1dor\u016F G1 a G2 jen ve 47 % . Ze studovan\u00FDch imunomarker\u016F m\u011Bly nejvy\u0161\u0161\u00ED expresi u prognosticky nep\u0159\u00EDzniv\u00FDch p\u0159\u00EDpad\u016F p53 , Ki 67 a c-erbB-2. U stejn\u00E9 skupiny tumor\u016F jsme prok\u00E1zali p\u0159\u00EDtomnost steroidn\u00EDch receptor\u016F jen v 58 %. Z\u00E1v\u011Br: Stanoven\u00ED DNA ploidity je v\u00FDznamn\u00FDm prognostick\u00FDm faktorem. Ze sledovan\u00FDch histopatologick\u00FDch imunomarker\u016F jsme prok\u00E1zali zv\u00FD\u0161enou expresi p53, Ki 67 a c-erbB-2 u prognosticky nep\u0159\u00EDzniv\u00FDch tumor\u016F . Sn\u00ED\u017Een\u00E1 p\u0159\u00EDtomnost steroidn\u00EDch receptor\u016F pak byla prok\u00E1z\u00E1na u stejn\u00E9 skupiny n\u00E1dor\u016F.." . "Prognostic importance of selected molecular genetic immunohistochemical markers and DNA ploidy in endometrial cancer."@en . "6"^^ . "Kudela, Milan" . . . "Prognostick\u00FD v\u00FDznam vybran\u00FDch molekul\u00E1rn\u011B-genetick\u00FDch imunohistochemick\u00FDch marker\u016F a DNA ploidity u karcinomu endometria." . "Endometrial cancer, DNA ploidy, molecular immunomarkers, prognostic factors"@en . "CZ - \u010Cesk\u00E1 republika" . "Prognostick\u00FD v\u00FDznam vybran\u00FDch molekul\u00E1rn\u011B-genetick\u00FDch imunohistochemick\u00FDch marker\u016F a DNA ploidity u karcinomu endometria."@cs . "Prognostick\u00FD v\u00FDznam vybran\u00FDch molekul\u00E1rn\u011B-genetick\u00FDch imunohistochemick\u00FDch marker\u016F a DNA ploidity u karcinomu endometria."@cs . "76" . . . . "1"^^ . "P(NS10272)" . "Prognostick\u00FD v\u00FDznam vybran\u00FDch molekul\u00E1rn\u011B-genetick\u00FDch imunohistochemick\u00FDch marker\u016F a DNA ploidity u karcinomu endometria. Anotace \u010Desky: C\u00EDl studie: Studium nov\u00FDch vybran\u00FDch molekul\u00E1rn\u011B genetick\u00FDch imunomarker\u016F ( p53, c-erbB-2, Ki 67, bcl-2), hormon\u00E1ln\u00EDch receptor\u016F (ER,PR) a zm\u011Bn v bun\u011B\u010Dn\u00E9 ploidit\u011B n\u00E1dorov\u00FDch bun\u011Bk endometri\u00E1ln\u00EDho karcinomu a jejich komparace s hlavn\u00EDmi prognostick\u00FDmi faktory . V\u00FDsledky: U 71 % biologicky nezral\u00FDch endometri\u00E1ln\u00EDch tumor\u016F ( G3) se \u0161patnou progn\u00F3zou jsme prok\u00E1zali p\u0159\u00EDtomnost aneuploidn\u00EDch karyotyp\u016F , zat\u00EDmco u n\u00E1dor\u016F G1 a G2 jen ve 47 % . Ze studovan\u00FDch imunomarker\u016F m\u011Bly nejvy\u0161\u0161\u00ED expresi u prognosticky nep\u0159\u00EDzniv\u00FDch p\u0159\u00EDpad\u016F p53 , Ki 67 a c-erbB-2. U stejn\u00E9 skupiny tumor\u016F jsme prok\u00E1zali p\u0159\u00EDtomnost steroidn\u00EDch receptor\u016F jen v 58 %. Z\u00E1v\u011Br: Stanoven\u00ED DNA ploidity je v\u00FDznamn\u00FDm prognostick\u00FDm faktorem. Ze sledovan\u00FDch histopatologick\u00FDch imunomarker\u016F jsme prok\u00E1zali zv\u00FD\u0161enou expresi p53, Ki 67 a c-erbB-2 u prognosticky nep\u0159\u00EDzniv\u00FDch tumor\u016F . Sn\u00ED\u017Een\u00E1 p\u0159\u00EDtomnost steroidn\u00EDch receptor\u016F pak byla prok\u00E1z\u00E1na u stejn\u00E9 skupiny n\u00E1dor\u016F.."@cs . . . . . . "Prognostic importance of selected molecular genetic immunohistochemical markers and DNA ploidy in endometrial cancer. Anotace anglicky: Objective: The aim of the study was the analysis of the new molecular genetic immunomarkers ( p53, c-erbB-2, Ki 67, bcl-2) hormonal receptors ( ER, PR) and ploidy disturbances and their relation to the most important prognostic factors for endometrial cancer. Results: Aneuploidy was found in 71 % in the group of poorly differentiated endometrial cancers ( G 3) in contrast to 47 % in the group of G1 and G2 tumours. High expression of p53 , Ki 67 , c-erbB-2 and low rate of sex hormone receptors was found in the prognostically unfavourable group ( G 3) Conclusions: Aneuploidy seems to be an important prognostical factor for endometrial cancer patients. Identification of p53, Ki 67, c-erbB-2 , ER a PR is a useful tool to specify a group of prognostically unfavourable patients."@en . . . "[D73268C05F0D]" . "6"^^ . "Lubu\u0161k\u00FD, Marek" . . . "1210-7832" . "\u010Cesk\u00E1 gynekologie" . "RIV/00098892:_____/11:#0000165" . "Prognostick\u00FD v\u00FDznam vybran\u00FDch molekul\u00E1rn\u011B-genetick\u00FDch imunohistochemick\u00FDch marker\u016F a DNA ploidity u karcinomu endometria." . .